As amyloid-targeting therapies for Alzheimer’s fail, where might success lie? (NYSE:LLY)
tupungato/iStock via Getty Images Mid- and late-stage data readouts over the last few years for Alzheimer’s therapies have had a similar theme: Failure. Almost all these candidates have one thing in common: They target reducing beta-amyloid plaque in the brain that is thought to play a role in the memory-robbing disease. However, the amyloid-targeting theme … Read more